A new Medicare drug price negotiation program that is being implemented by the US Centers for Medicare & Medicaid Services (CMS) as required by the Inflation Reduction Act (IRA) is already having an impact on research and development investment decisions, Eli Lilly and Company CEO David Ricks said during an investor event sponsored by J.P. Morgan on 14 June to discuss the IRA and pharmaceutical industry policy priorities.
Lilly Sidelined Three Drugs Due To IRA, CEO Ricks Says
Eli Lilly & Co. CEO David Ricks highlighted how Medicare drug price negotiation policies are already impacting R&D investment during a J.P. Morgan investor call.
